Medical Prosthetics Company for Sale in Hong Kong

Products and services:
- AI embryo assessment: 3D‑TCNN deep learning analyzes multi‑timepoint images and outputs scores and implantation probability in ~30 seconds per embryo. Accuracy is ~87% with strong sensitivity and specificity.
- Integration: Standardized interfaces connect to major incubators and microscopes for real-time capture, task scheduling, and results write-back into the lab workflow.
- Automated reports and compliance: Patient linking, templated reports, RBAC, and audit logs; designed for HIPAA, ISO 13485/14971/62304, and FDA/EU MDR SaMD compliance.
- Deployment options: On-premises, cloud SaaS, or hybrid solutions to accommodate large centers’ security requirements and smaller clinics’ fast rollout.
Who uses it and how:
- Users: IVF centers, fertility clinics, hospital groups, and research labs for embryo grading, transfer decision support, and QA dashboards.
- Usage: From fertilization to blastocyst, the system automatically ingests time-lapse images, generates rankings and transfer timing guidance, and integrates into a staged rollout from observation to primary decision support. The business doesn't have any physical assets of significant value.
Intangible: Granted and pending AI medical technology patents (including IVF workflow optimization and embryo assessment), proprietary algorithms & trained models, software source code repositories, datasets & annotation IP, trademarks & brand assets, documented SOPs, regulatory correspondence, vendor & client contracts, and know‑how transferred by key staff at closing - all valued at HKD 350 million. Facility description:
No dedicated physical office facility is required.
- Operations are software-centric with flexible deployment options: on-premises data center racks within partner hospitals, cloud SaaS, or hybrid setups with local inference and centralized management.
- On-premises projects include secured servers, storage, and network appliances integrated with incubators/cameras; disaster recovery, RBAC, and full audit logging are standard.
- Typical implementation spans 6–8 weeks for hardware installation, protocol integration, end-to-end testing, and clinical verification before go-live under the staged adoption plan. Self-funded.
No outstanding loans.
There is 1 owner with 100% shareholding.